ArticleNeuropharmacology2018
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction (Abingdon, England) · 2025Trial
- Integrating Pain Assessment in Nicotine and Tobacco Research and Treatment to Improve Cessation Outcomes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Integrative biochemical and computational evaluation of methyl eugenol, naphthalene, and linalool as natural multitarget therapeutics for smoking cessation-related metabolic disturbances.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effects of commercial unflavored and vanilla-flavored e-liquids on nicotine intake and withdrawal.bioRxiv : the preprint server for biology · 2026Article
- Drug screening targeting TREM2-TYROBP transmembrane binding.Molecular medicine (Cambridge, Mass.) · 2025Article
- Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy.Psychopharmacology · 2024Article
- Bupropion and varenicline administration reversed depressive behavior induced by acetamiprid exposure in mice: the role of nAChRs in depression.Toxicology research · 2024Article
- Sex differences in nicotine intake and relapse behavior in nicotine-dependent adult wistar rats.Frontiers in pharmacology · 2024Article
- Chronic alcohol induced mechanical allodynia by promoting neuroinflammation: A mouse model of alcohol-evoked neuropathic pain.British journal of pharmacology · 2023Article
- Rare coding variants in CHRNB2 reduce the likelihood of smoking.Nature genetics · 2023Article
- Development of Dependence in Smokers and Rodents With Voluntary Nicotine Intake: Similarities and Differences.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Review
- Evaluation of novel epibatidine analogs in the rat nicotine drug discrimination assay and in the rat chronic constriction injury neuropathic pain model.Advances in drug and alcohol research · 2023Article
- Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.Cell communication and signaling : CCS · 2022Article
- Sensory Effects of Nicotine and Tobacco.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022Review
- Animal Models to Investigate the Impact of Flavors on Nicotine Addiction and Dependence.Current neuropharmacology · 2022Review
- Prevalence and impact of comorbid chronic pain and cigarette smoking among people living with HIV.AIDS care · 2021Article
- Rodent models for nicotine withdrawal.Journal of psychopharmacology (Oxford, England) · 2021Review
- Pain and smoking study (PASS): A comparative effectiveness trial of smoking cessation counseling for veterans with chronic pain.Contemporary clinical trials communications · 2021Article
- Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats.Psychopharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Varenicline, a partial agonist for α4β2* nicotinic acetylcholine receptors (nAChRs) and a full agonist for α3β4 and α7 nAChRs, is approved for smoking cessation treatment. Although, partial agonism at α4β2* nAChRs is believed to be the mechanism underlying the effects of varenicline on nicotine reward, the contribution of other nicotinic subtypes to varenicline's effects on nicotine reward is currently unknown. Therefore, we examined the role of α5 and α7 nAChR subunits in the effects of varenicline on nicotine reward using the conditioned place preference (CPP) test in mice. Moreover, the effects of varenicline on nicotine withdrawal-induced hyperalgesia and aversion are unknown. We also examined the reversal of nicotine withdrawal in mouse models of dependence by varenicline. Varenicline dose-dependently blocked the development and expression of nicotine reward in the CPP test. The blockade of nicotine reward by varenicline (0.1 mg/kg) was preserved in α7 knockout mice but reduced in α5 knockout mice. Administration of varenicline at high dose of 2.5 mg/kg resulted in a place aversion that was dependent on α5 nAChRs but not β2 nAChRs. Furthermore, varenicline (0.1 and 0.5 mg/kg) reversed nicotine withdrawal signs such as hyperalgesia and somatic signs and withdrawal-induced aversion in a dose-related manner. Our results indicate that the α5 nAChR subunit plays a role in the effects of varenicline on nicotine reward in mice. Moreover, the mediation of α5 nAChRs, but not β2 nAChRs are probably needed for aversive properties of varenicline at high dose. Varenicline was also shown to reduce several nicotine withdrawal signs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.